Dylan A Mordaunt (Victoria University of Wellington – Te Herenga Waka; University of Melbourne, Melbourne School of Population and Global Health, Students; Flinders University – College of Medicine and Public Health) has posted Executive Override and Clinical Governance: The Queensland Puberty Blocker Directive in Administrative Law Context on SSRN. Here is the abstract:
On a Tuesday morning in late October 2025, the Queensland Supreme Court handed down a decision that should make every clinician in Australia stop and reflect. The Court ruled that a Queensland Health directive banning new prescriptions of puberty blockers for young people with gender dysphoria was unlawful, primarily because the required consultation was inadequate. The consultation lasted just twenty-two minutes and occurred simultaneously with the Minister’s press conference. Justice Peter Callaghan described this process as “functionally irrelevant”. This article describes why all health practitioners and consumers in Queensland should be concerned, whether you are supportive or “opposed” to gender affirming care.
Also, by the same author: The Architecture of Exception: A Multi-Dimensional Analysis of the 2025 New Zealand Puberty Blocker Ban.